2023
Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection
Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection. Small Methods 2023, 7: e2300594. PMID: 37312418, PMCID: PMC10592458, DOI: 10.1002/smtd.202300594.Peer-Reviewed Original ResearchConceptsB cell depletion therapyAcute COVID infectionAnti-spike IgGHigh-risk patientsCoronavirus disease-19COVID-19 pathologyDepletion therapyVaccine protectionAntibody responseCOVID infectionHematologic malignanciesImmune protectionDisease-19Healthy donorsMultiple time pointsSerology assaysBlood samplesSoluble markersB cellsImmunization strategiesPatientsFunctional deficiencySerological analysisTime pointsClonotype diversity
2015
Computational Approach to Annotating Variants of Unknown Significance in Clinical Next Generation Sequencing
Schulz WL, Tormey CA, Torres R. Computational Approach to Annotating Variants of Unknown Significance in Clinical Next Generation Sequencing. Lab Medicine 2015, 46: 285-289. PMID: 26489672, DOI: 10.1309/lmwzh57brwopr5rq.Peer-Reviewed Original ResearchConceptsNext-generation sequencingClinical significanceUnknown clinical significanceMalignant neoplasmsHematologic malignanciesClinical next-generation sequencingSoftware algorithmsGeneration sequencingUnknown significanceBenign variantsConflicting resultsClinical laboratoriesComputational toolsCommon technologyAlgorithm